Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) and Mosaic ImmunoEngineering (OTCMKTS:CPMV)

NeuroSense Therapeutics (NASDAQ:NRSN) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Earnings & Valuation

This table compares NeuroSense Therapeutics and Mosaic ImmunoEngineering”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$10.21 million	($0.54)	-1.71
Mosaic ImmunoEngineering	N/A	N/A	-$920,000.00	($0.09)	-7.20

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for NeuroSense Therapeutics and Mosaic ImmunoEngineering, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1	1	1	2	2.80
Mosaic ImmunoEngineering	0	0	0	0	0.00

NeuroSense Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 1,415.64%. Given NeuroSense Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than Mosaic ImmunoEngineering.

Risk and Volatility

NeuroSense Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of -0.82, suggesting that its stock price is 182% less volatile than the S&P 500.

Profitability

This table compares NeuroSense Therapeutics and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Mosaic ImmunoEngineering	N/A	N/A	-761.65%

Institutional and Insider Ownership

1.0% of NeuroSense Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

NeuroSense Therapeutics beats Mosaic ImmunoEngineering on 8 of the 11 factors compared between the two stocks.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.